Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression

Human Molecular Genetics

Volumn 24, Issue 18, 2015, Pages 5299-5312

  Liu, Guoxiang ^a,b   Sgobio, Carmelo ^a   Gu, Xinglong ^a,e   Sun, Lixin ^a   Lin, Xian ^a,f   Yu, Jia ^a   Parisiadou, Loukia ^a,b   Xie, Chengsong ^a   Sastry, Namratha ^a,b   Ding, Jinhui ^a   Lohr, Kelly M ^c   Miller, Gary W ^c   Mateo, Yolanda ^d   Lovinger, David M ^d   Cai, Huaibin ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; DOPAMINE; DOPAMINE TRANSPORTER; G2019S PROTEIN; GENOMIC DNA; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; PROTEIN; TRANSCRIPTION FACTOR PITX3; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; HOMEODOMAIN PROTEIN; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GENE EXPRESSION SYSTEM; GENE OVEREXPRESSION; HOMEOSTASIS; MALE; MESENCEPHALON; MISSENSE MUTATION; MOUSE; NERVE CELL DEGENERATION; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; WILD TYPE; AGE; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOTOR ACTIVITY; NERVE DEGENERATION; PATHOLOGY; SUBSTANTIA NIGRA;

AGE FACTORS; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MESENCEPHALON; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUTATION, MISSENSE; NERVE DEGENERATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SUBSTANTIA NIGRA; TRANSCRIPTION FACTORS;

EID: 84940659719     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv249     Document Type: Article

References (59)

1. Parkinson, J. (1817) An Essay on the Shaking Palsy. Sherwood, Nelly and Jones, London.
2. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med., 339, 1044-1053.
3. Davie, C.A. (2008) A review of Parkinson's disease. Br. Med. Bull., 86, 109-127.
4. Cotzias, G.C. (1968) L-Dopa for Parkinsonism. N. Engl. J. Med., 278, 630.
5. Pankratz, N.D., Wojcieszek, J. and Foroud, T. (1993) Parkinson disease overview. In Pagon, R.A., Adam, M.P., Bird, T.D., Dolan, C.R., Fong, C.T. and Stephens, K. (eds), GeneReviews, Seattle, WA. 1993-2004 May 25 [updated 2009 July 9]. http://www.genetest.org.
6. Hardy, J., Cai, H., Cookson, M.R., Gwinn-Hardy, K. and Singleton, A. (2006) Genetics of Parkinson's disease and parkinsonism. Ann. Neurol., 60, 389-398.
7. Martin, I., Dawson, V.L. and Dawson, T.M. (2011) Recent advances in the genetics of Parkinson's disease. Annu. Rev. Genomics Hum. Genet., 12, 301-325.
8. Anand, V.S. and Braithwaite, S.P. (2009) LRRK2 in Parkinson's disease: biochemical functions. FEBS J., 276, 6428-6435.
9. Imai, Y., Gehrke, S., Wang, H.Q., Takahashi, R., Hasegawa, K., Oota, E. and Lu, B. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J., 27, 2432-2443.
10. Gehrke, S., Imai, Y., Sokol, N. and Lu, B. (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature, 466, 637-641.
11. Martin, I., Kim, J.W., Lee, B.D., Kang, H.C., Xu, J.C., Jia, H., Stankowski, J., Kim, M.S., Zhong, J., Kumar, M. et al. (2014) Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. Cell, 157, 472-485.
12. Cho, H.J., Yu, J., Xie, C., Rudrabhatla, P., Chen, X., Wu, J., Parisiadou, L., Liu, G., Sun, L., Ma, B. et al. (2014) Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ERGolgi export. EMBO J., 33, 2314-2331.
13. Parisiadou, L. and Cai, H. (2010) LRRK2 function on actin and microtubule dynamics in Parkinson disease. Commun. Integr. Biol., 3, 396-400.
14. Dodson, M.W., Zhang, T., Jiang, C., Chen, S. and Guo, M. (2012) Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning. Hum. Mol. Genet., 21, 1350-1363.
15. Alegre-Abarrategui, J., Christian, H., Lufino, M.M., Mutihac, R., Venda, L.L., Ansorge, O. and Wade-Martins, R. (2009) LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet., 18, 4022-4034.
16. Matta, S., Van Kolen, K., da Cunha, R., van den Bogaart, G., Mandemakers, W., Miskiewicz, K., De Bock, P.J., Morais, V.A., Vilain, S., Haddad, D. et al. (2012) LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron, 75, 1008-1021.
17. Parisiadou, L., Yu, J., Sgobio, C., Xie, C., Liu, G., Sun, L., Gu, X.L., Lin, X., Crowley, N.A., Lovinger, D.M. et al. (2014) LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat. Neurosci., 17, 367-376.
18. Beccano-Kelly, D.A., Volta, M., Munsie, L.N., Paschall, S.A., Tatarnikov, I., Co, K., Chou, P., Cao, L.P., Bergeron, S., Mitchell, E. et al. (2014) LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum. Mol. Genet., 24, 1336-1349.
19. Tong, Y., Pisani, A., Martella, G., Karouani, M., Yamaguchi, H., Pothos, E.N. and Shen, J. (2009) R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc. Natl Acad. Sci. USA, 106, 14622-14627.
20. Li, Y., Liu, W., Oo, T.F., Wang, L., Tang, Y., Jackson-Lewis, V., Zhou, C., Geghman, K., Bogdanov, M., Przedborski, S. et al. (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci., 12, 826-828.
21. Li, X., Patel, J.C., Wang, J., Avshalumov, M.V., Nicholson, C., Buxbaum, J.D., Elder, G.A., Rice, M.E. and Yue, Z. (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci., 30, 1788-1797.
22. Giesert, F., Hofmann, A., Burger, A., Zerle, J., Kloos, K., Hafen, U., Ernst, L., Zhang, J., Vogt-Weisenhorn, D.M. and Wurst, W. (2013) Expression analysis of lrrk1, lrrk2 and lrrk2 splice variants in mice. PLoS ONE, 8, e63778.
23. Higashi, S., Biskup, S., West, A.B., Trinkaus, D., Dawson, V.L., Faull, R.L., Waldvogel, H.J., Arai, H., Dawson, T.M., Moore, D.J. et al. (2007) Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res., 1155, 208-219.
24. Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R.J., III and Shen, J. (2010) Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA, 107, 9879-9884.
25. Lin, X., Parisiadou, L., Gu, X.L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.X., Yang, W.J., Ding, J. et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alphasynuclein. Neuron, 64, 807-827.
26. Hinkle, K.M., Yue, M., Behrouz, B., Dachsel, J.C., Lincoln, S.J., Bowles, E.E., Beevers, J.E., Dugger, B., Winner, B., Prots, I. et al. (2012) LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors. Mol. Neurodegener., 7, 25.
27. Daniel, G. and Moore, D.J. (2014) Modeling LRRK2 pathobiology in Parkinson's disease: from yeast to rodents. Curr. Top. Behav. Neurosci., 22, 331-368.
28. Yue, Z. (2012) Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application. Parkinsonism Relat. Disord., 18(Suppl. 1), S180-S182.
29. Smidt, M.P. and Burbach, J.P. (2009) Terminal differentiation of mesodiencephalic dopaminergic neurons: the role of Nurr1 and Pitx3. Adv. Exp. Med. Biol., 651, 47-57.
30. Smidt, M.P., Smits, S.M., Bouwmeester, H., Hamers, F.P., van der Linden, A.J., Hellemons, A.J., Graw, J. and Burbach, J.P. (2004) Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development, 131, 1145-1155.
31. Lin, X., Parisiadou, L., Sgobio, C., Liu, G., Yu, J., Sun, L., Shim, H., Gu, X.L., Luo, J., Long, C.X. et al. (2012) Conditional expression of Parkinson's disease-related mutant alphasynuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J. Neurosci., 32, 9248-9264.
32. Gerfen, C.R. and Surmeier, D.J. (2011) Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci., 34, 441-466.
33. Goldstein, D.S., Sullivan, P., Holmes, C., Miller, G.W., Alter, S., Strong, R., Mash, D.C., Kopin, I.J. and Sharabi, Y. (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J. Neurochem., 126, 591-603.
34. Liu, G., Yu, J., Ding, J., Xie, C., Sun, L., Rudenko, I., Zheng, W., Sastry, N., Luo, J., Rudow, G. et al. (2014) Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation. J. Clin. Invest., 124, 3032-3046.
35. Jacobs, F.M., Veenvliet, J.V., Almirza, W.H., Hoekstra, E.J., von Oerthel, L., van der Linden, A.J., Neijts, R., Koerkamp, M.G., van Leenen, D., Holstege, F.C. et al. (2011) Retinoic acid-dependent and-independent gene-regulatory pathways of Pitx3 in meso-diencephalic dopaminergic neurons. Development, 138, 5213-5222.
36. Decressac, M., Volakakis, N., Bjorklund, A. and Perlmann, T. (2013) NURR1 in Parkinson disease-from pathogenesis to therapeutic potential. Nat. Rev. Neurol., 9, 629-636.
37. Ramonet, D., Daher, J.P., Lin, B.M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L. et al. (2011) Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE, 6, e18568.
38. Melrose, H.L., Dachsel, J.C., Behrouz, B., Lincoln, S.J., Yue, M., Hinkle, K.M., Kent, C.B., Korvatska, E., Taylor, J.P., Witten, L. et al. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol. Dis., 40, 503-517.
39. Herzig, M.C., Kolly, C., Persohn, E., Theil, D., Schweizer, T., Hafner, T., Stemmelen, C., Troxler, T.J., Schmid, P., Danner, S. et al. (2011) LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum. Mol. Genet., 20, 4209-4223.
40. Bonifati, V. (2007) LRRK2 low-penetrance mutations (Gly2019-Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem. Res., 32, 1700-1708.
41. Bonifati, V. (2006) The pleomorphic pathology of inherited Parkinson's disease: lessons fromLRRK2. Curr. Neurol. Neurosci. Rep., 6, 355-357.
42. Latourelle, J.C., Sun, M., Lew, M.F., Suchowersky, O., Klein, C., Golbe, L.I., Mark, M.H., Growdon, J.H., Wooten, G.F., Watts, R.L. et al. (2008) The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med., 6, 32.
43. Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O. and Olson, L. (2006) LRRK2 expression linked to dopamineinnervated areas. Ann. Neurol., 59, 714-719.
44. Melrose, H., Lincoln, S., Tyndall, G., Dickson, D. and Farrer, M. (2006) Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience, 139, 791-794.
45. Mandemakers, W., Snellinx, A., O'Neill, M.J. and de Strooper, B. (2012) LRRK2 expression is enriched in the striosomal compartment of mouse striatum. Neurobiol. Dis., 48, 582-593.
46. Davies, P., Hinkle, K.M., Sukar, N.N., Sepulveda, B., Mesias, R., Serrano, G., Alessi, D.R., Beach, T.G., Benson, D.L., White Iii, C. L. et al. (2013) Comprehensive characterization and optimization of leucine rich repeat kinase 2 (LRRK2) monoclonal antibodies. Biochem. J., 453, 101-113.
47. Watabe-Uchida, M., Zhu, L., Ogawa, S.K., Vamanrao, A. and Uchida, N. (2012) Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron, 74, 858-873.
48. Crittenden, J.R. and Graybiel, A.M. (2011) Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Front. Neuroanat., 5, 59.
49. Moehle, M.S., Webber, P.J., Tse, T., Sukar, N., Standaert, D.G., DeSilva, T.M., Cowell, R.M. andWest, A.B. (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci., 32, 1602-1611.
50. Kim, B., Yang, M.S., Choi, D., Kim, J.H., Kim, H.S., Seol, W., Choi, S., Jou, I., Kim, E.Y. and Joe, E.H. (2012) Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS ONE, 7, e34693.
51. Aguzzi, A., Barres, B.A. and Bennett, M.L. (2013) Microglia: scapegoat, saboteur, or something else? Science, 339, 156-161.
52. Zhou, H., Huang, C., Tong, J., Hong, W.C., Liu, Y.J. and Xia, X.G. (2011) Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int. J. Biol. Sci., 7, 753-761.
53. Lee, S., Liu, H.P., Lin, W.Y., Guo, H. and Lu, B. (2010) LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J. Neurosci., 30, 16959-16969.
54. Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., Carta, M., Muramatsu, S., Sumi-Ichinose, C., Nomura, T., Metzger, D. et al. (2009) Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci., 29, 15923-15932.
55. Zetterstrom, R.H., Solomin, L., Jansson, L., Hoffer, B.J., Olson, L. and Perlmann, T. (1997) Dopamine neuron agenesis in Nurr1-deficient mice. Science, 276, 248-250.
56. Lohr, K.M., Bernstein, A.I., Stout, K.A., Dunn, A.R., Lazo, C.R., Alter, S.P., Wang, M., Li, Y., Fan, X., Hess, E.J. et al. (2014) Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo. Proc. Natl Acad. Sci. USA, 111, 9977-9982.
57. Lai, C., Lin, X., Chandran, J., Shim, H., Yang, W.J. and Cai, H. (2007) The G59S mutation in p150(glued) causes dysfunction of dynactin in mice. J. Neurosci., 27, 13982-13990.
58. Yorgason, J.T., Espana, R.A. and Jones, S.R. (2011) Demon voltammetry and analysis software: analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. J. Neurosci. Methods, 202, 158-164.
59. Carey, R.J. and DePalma, G. (1994) A simplified method for the measurement of caffeine in plasma and brain: evidence for a cortical-subcortical caffeine concentration differential in brain. J. Neurosci. Methods, 53, 19-22.